TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
9.06
+0.05 (0.55%)
May 29, 2026, 1:30 PM CST
TPEX:4157 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 121 | 145.09 | 74.14 | 374.66 | 243.11 | 364.93 |
Short-Term Investments | 762.66 | 674.82 | 751.28 | 598.2 | 591.11 | 495.38 |
Trading Asset Securities | 77.28 | 206.84 | 194.4 | 65.14 | 64.39 | 64.09 |
Cash & Short-Term Investments | 960.94 | 1,027 | 1,020 | 1,038 | 898.6 | 924.4 |
Cash Growth | -5.67% | 0.68% | -1.75% | 15.51% | -2.79% | 179.46% |
Accounts Receivable | 4.43 | 5.01 | 7.33 | 8.98 | 18.41 | 278.28 |
Other Receivables | 8.73 | 7.93 | 9.07 | 24.88 | 5.3 | 2.61 |
Receivables | 13.16 | 12.94 | 16.4 | 33.87 | 23.71 | 280.89 |
Inventory | 71.16 | 76.1 | 42.71 | 34.15 | 15.35 | 17.88 |
Other Current Assets | 2.17 | 4.15 | 7.16 | 4.37 | 11.57 | 8.84 |
Total Current Assets | 1,047 | 1,120 | 1,086 | 1,110 | 949.24 | 1,232 |
Property, Plant & Equipment | 15.64 | 17.31 | 67.47 | 90.61 | 56.6 | 80.43 |
Long-Term Investments | 2.69 | 3.41 | 2.45 | 9.71 | 23.98 | 53.9 |
Other Intangible Assets | 40.47 | 22.45 | 12.05 | 12.99 | 0.23 | 0.16 |
Other Long-Term Assets | 3.58 | 4.15 | 6.22 | 6.16 | 16.96 | 26.31 |
Total Assets | 1,110 | 1,167 | 1,174 | 1,230 | 1,047 | 1,393 |
Short-Term Debt | - | 35 | - | - | 3 | - |
Current Portion of Leases | 5.63 | 5.6 | 16.33 | 15.98 | 18.34 | 17.99 |
Current Income Taxes Payable | - | - | 0.11 | - | 3.07 | 27.86 |
Current Unearned Revenue | 6.54 | 0.15 | 0.15 | 0.15 | 0.15 | 0.18 |
Other Current Liabilities | 41.99 | 42.36 | 29.5 | 31.76 | 26.76 | 43.85 |
Total Current Liabilities | 54.16 | 83.11 | 46.08 | 47.89 | 51.32 | 89.88 |
Long-Term Leases | 7.2 | 8.62 | 42.39 | 58.71 | 17.13 | 35.47 |
Long-Term Unearned Revenue | - | 0.03 | 0.18 | 0.33 | 0.48 | 0.62 |
Pension & Post-Retirement Benefits | 0.59 | 0.63 | 3.31 | 4.01 | 8.05 | 13.15 |
Total Liabilities | 61.95 | 92.38 | 91.96 | 110.94 | 76.98 | 139.11 |
Common Stock | 20.77 | 20.77 | 20.94 | 20.94 | 20.91 | 20.91 |
Additional Paid-In Capital | 451.81 | 451.17 | 466.3 | 444.61 | 450.26 | 455.25 |
Retained Earnings | 620 | 634.32 | 640.6 | 678.68 | 542.05 | 778.3 |
Comprehensive Income & Other | -44.73 | -31.38 | -45.51 | -25.34 | -43.2 | -0.77 |
Shareholders' Equity | 1,048 | 1,075 | 1,082 | 1,119 | 970.03 | 1,254 |
Total Liabilities & Equity | 1,110 | 1,167 | 1,174 | 1,230 | 1,047 | 1,393 |
Total Debt | 12.83 | 49.22 | 58.71 | 74.69 | 38.47 | 53.46 |
Net Cash (Debt) | 948.11 | 977.54 | 961.11 | 963.3 | 860.13 | 870.94 |
Net Cash Growth | 2.05% | 1.71% | -0.23% | 12.00% | -1.24% | 177.67% |
Net Cash Per Share | 1.34 | 1.37 | 1.34 | 1.34 | 1.20 | 1.21 |
Filing Date Shares Outstanding | 716.2 | 711.83 | 717.84 | 717.84 | 716.84 | 716.84 |
Total Common Shares Outstanding | 716.2 | 711.83 | 717.84 | 717.84 | 716.84 | 716.84 |
Working Capital | 993.27 | 1,037 | 1,040 | 1,062 | 897.92 | 1,142 |
Book Value Per Share | 1.46 | 1.51 | 1.51 | 1.56 | 1.35 | 1.75 |
Tangible Book Value | 1,007 | 1,052 | 1,070 | 1,106 | 969.8 | 1,254 |
Tangible Book Value Per Share | 1.41 | 1.48 | 1.49 | 1.54 | 1.35 | 1.75 |
Machinery | - | 25.54 | 144.93 | 144.38 | 143.76 | 140.92 |
Leasehold Improvements | - | 1.79 | 60.79 | 60.66 | 60.71 | 60.67 |